Jama Network
JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:13:02
- More information
Informações:
Synopsis
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.